X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1001) 1001
Publication (120) 120
Book Chapter (19) 19
Book Review (19) 19
Conference Proceeding (7) 7
Dissertation (4) 4
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (479) 479
humans (440) 440
animals (407) 407
pde4 (364) 364
pharmacology & pharmacy (303) 303
pde4 inhibitors (249) 249
pde4 inhibitor (247) 247
male (244) 244
asthma (203) 203
rats (185) 185
cyclic nucleotide phosphodiesterases, type 4 (177) 177
chemistry, medicinal (176) 176
roflumilast (172) 172
obstructive pulmonary-disease (168) 168
rolipram (168) 168
phosphodiesterase inhibitors - pharmacology (167) 167
phosphodiesterase (160) 160
mice (145) 145
camp (142) 142
inflammation (142) 142
cyclic nucleotide phosphodiesterases, type 4 - metabolism (140) 140
female (130) 130
copd (124) 124
phosphodiesterase 4 inhibitors - pharmacology (124) 124
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (120) 120
chemistry, organic (111) 111
biochemistry & molecular biology (109) 109
cyclic amp - metabolism (102) 102
rolipram - pharmacology (95) 95
dose-response relationship, drug (93) 93
in-vitro (90) 90
chronic obstructive pulmonary disease (89) 89
analysis (88) 88
neurosciences (84) 84
phosphodiesterase 4 inhibitors - therapeutic use (84) 84
benzamides - pharmacology (80) 80
cyclic-nucleotide phosphodiesterases (80) 80
pulmonary disease, chronic obstructive - drug therapy (80) 80
expression (79) 79
respiratory system (78) 78
inhibitors (77) 77
phosphodiesterase-4 inhibitor (76) 76
structure-activity relationship (76) 76
aminopyridines - pharmacology (75) 75
adult (73) 73
cyclopropanes - pharmacology (71) 71
phosphodiesterase inhibitors - therapeutic use (71) 71
rats, sprague-dawley (71) 71
cell biology (70) 70
phosphodiesterase 4 inhibitors (68) 68
3',5'-cyclic-amp phosphodiesterases - metabolism (66) 66
disease models, animal (64) 64
derivatives (61) 61
middle aged (61) 61
psoriasis (61) 61
administration, oral (59) 59
phosphodiesterase-4 (59) 59
aminopyridines - therapeutic use (58) 58
benzamides - therapeutic use (58) 58
asthma - drug therapy (56) 56
enzymes (56) 56
cyclic-amp (55) 55
cyclopropanes - therapeutic use (55) 55
article (54) 54
camp-specific phosphodiesterase (54) 54
efficacy (54) 54
drug design (52) 52
cyclic amp (51) 51
immunology (51) 51
models, molecular (51) 51
phosphorylation (51) 51
phosphodiesterase 4 inhibitors - chemistry (50) 50
molecular structure (49) 49
lung diseases, obstructive (48) 48
apremilast (46) 46
necrosis-factor-alpha (46) 46
phosphodiesterase 4 (46) 46
phosphodiesterase inhibitors - chemistry (46) 46
cells, cultured (45) 45
drug therapy (45) 45
pharmacology (45) 45
pde4 inhibitor roflumilast (44) 44
proteins (44) 44
atopic dermatitis (43) 43
memory (43) 43
phosphodiesterase inhibitors (43) 43
activation (42) 42
cyclic adenylic acid (42) 42
rodents (42) 42
dermatology (41) 41
safety (41) 41
mice, inbred c57bl (40) 40
signal transduction - drug effects (40) 40
cyclic amp-dependent protein kinases - metabolism (39) 39
cytokines (39) 39
disease (39) 39
phosphodiesterase inhibitors - administration & dosage (39) 39
research (39) 39
treatment outcome (39) 39
aminopyridines - adverse effects (37) 37
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1000) 1000
German (8) 8
French (6) 6
Japanese (3) 3
Spanish (2) 2
Chinese (1) 1
Czech (1) 1
Korean (1) 1
Polish (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Dermatologic Therapy, ISSN 1396-0296, 11/2017, Volume 30, Issue 6, pp. e12555 - n/a
The rapid progress of genetic engineering furthermore opens up new prospects in the therapy of this difficult‐to‐treat disease. IL‐23 inhibitors,... 
treatment | PDE4 inhibitors | psoriasis | therapy | biological drugs | immune‐modulating | IL‐23 inhibitors | JAK inhibitors | IL-23 inhibitors | immune-modulating | CONTROLLED-TRIAL | MODERATE | EFFICACY | SAFETY | PHASE-III | GUSELKUMAB | INTERLEUKIN-23 | DERMATOLOGY | APREMILAST | PLAQUE PSORIASIS | TILDRAKIZUMAB | Interleukin-23 Subunit p19 - antagonists & inhibitors | Humans | Psoriasis - diagnosis | Dermatologic Agents - therapeutic use | Janus Kinases - metabolism | Molecular Targeted Therapy | Dermatologic Agents - adverse effects | Interleukin-23 Subunit p19 - metabolism | Phosphodiesterase 4 Inhibitors - adverse effects | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Skin - pathology | Skin - immunology | Psoriasis - immunology | Psoriasis - drug therapy | Phosphodiesterase 4 Inhibitors - therapeutic use | Treatment Outcome | Skin - enzymology | Janus Kinases - antagonists & inhibitors | Janus Kinase Inhibitors - adverse effects | Animals | Janus Kinase Inhibitors - therapeutic use | Signal Transduction - drug effects | Cyclic Nucleotide Phosphodiesterases, Type 4 - immunology | Interleukin-23 Subunit p19 - immunology | Psoriasis - enzymology | Skin - drug effects | Psoriasis | Interleukins | Dermatology | Formulae, receipts, prescriptions | Monoclonal antibodies | Mutual fund industry | Dermatologic agents | Genetic engineering | Drug therapy
Journal Article
Journal Article
European Journal of Pharmacology, ISSN 0014-2999, 03/2006, Volume 533, Issue 1-3, pp. 110 - 117
Phosphodiesterases hydrolyse intracellular cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) into inactive 5′... 
Phosphodiesterase inhibitor | Rolipram | Chronic obstructive pulmonary disease | Roflumilast | Cilomilast | Phosphodiesterase | Asthma | roflumilast | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | EOSINOPHIL INFILTRATION | rolipram | asthma | NECROSIS-FACTOR-ALPHA | GM-CSF RELEASE | PDE4 INHIBITORS | OBSTRUCTIVE PULMONARY-DISEASE | phosphodiesterase inhibitor | CAMP-PHOSPHODIESTERASES | PHARMACOLOGY & PHARMACY | CD8(+) T-LYMPHOCYTES | phosphodiesterase | TNF-ALPHA | cilomilast | ANTIINFLAMMATORY DRUGS | chronic obstructive pulmonary disease | Phosphodiesterase Inhibitors - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 4 | Nitriles - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 5 | Humans | Cyclopropanes - therapeutic use | Benzamides - therapeutic use | Aminopyridines - therapeutic use | Isoenzymes - metabolism | Anti-Inflammatory Agents - therapeutic use | Carboxylic Acids - therapeutic use | Benzamides - pharmacology | Carboxylic Acids - pharmacology | Cyclopropanes - pharmacology | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | Phosphoric Diester Hydrolases - metabolism | Anti-Inflammatory Agents - pharmacology | Asthma - enzymology | Phosphodiesterase Inhibitors - pharmacology | Clinical Trials as Topic | Asthma - drug therapy | Pulmonary Disease, Chronic Obstructive - enzymology | Animals | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | Aminopyridines - pharmacology | 3',5'-Cyclic-GMP Phosphodiesterases | Cyclohexanecarboxylic Acids | Cyclic Nucleotide Phosphodiesterases, Type 7 | Isoenzymes - antagonists & inhibitors | Nitriles - therapeutic use | Pulmonary Disease, Chronic Obstructive - drug therapy | Hydrolysis | Hypertension | Isoenzymes | Guanosine | Cyclic adenylic acid | Esterases | T cells | Adenylic acid | Cyclic guanylic acid
Journal Article
Cellular Signalling, ISSN 0898-6568, 09/2014, Volume 26, Issue 9, pp. 2016 - 2029
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in... 
Phosphodiesterase inhibitor | Apremilast | Spondyloarthropathies | Psoriasis | Preclinical drug evaluation | Psoriatic arthritis | PROTEIN-KINASE-A | CONTROLLED-TRIAL | CAMP-SPECIFIC PHOSPHODIESTERASE | NECROSIS-FACTOR-ALPHA | KAPPA-B | PSORIATIC-ARTHRITIS | CELL BIOLOGY | ORAL PHOSPHODIESTERASE-4 INHIBITOR | CYCLIC-AMP | THALIDOMIDE ANALOGS | B-MEDIATED TRANSCRIPTION | Thalidomide - metabolism | Humans | Male | Thalidomide - pharmacology | Lung Diseases - drug therapy | Thalidomide - analogs & derivatives | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Female | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Vomiting - prevention & control | B-Lymphocytes - metabolism | Disease Models, Animal | Cell Line | Cytokines - metabolism | Immunity, Innate - drug effects | Jurkat Cells | Phosphodiesterase 4 Inhibitors - therapeutic use | Mice, Transgenic | Phosphodiesterase 4 Inhibitors - metabolism | Ferrets | Phosphodiesterase 4 Inhibitors - pharmacology | B-Lymphocytes - drug effects | Adaptive Immunity - drug effects | Animals | B-Lymphocytes - immunology | Protein Binding | T-Lymphocytes - immunology | Mice | Thalidomide - therapeutic use | Dendritic cells | Analysis | Development and progression | Genetic engineering | B cells | Biological response modifiers | T cells
Journal Article
Journal Article
European Journal of Medicinal Chemistry, ISSN 0223-5234, 04/2018, Volume 150, pp. 742 - 756
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 07/2018, Volume 61, Issue 13, pp. 5467 - 5483
Journal Article
Journal Article